NEW YORK (GenomeWeb) – HTG Molecular Diagnostics announced today that it has signed distribution agreements with Gamidor Diagnostics and Durviz s.l. Parque Tecnológico de Valencia to distribute its next-generation sequencing-based products in Israel, and Spain and Portugal, respectively. 

Gamidor sells diagnostic systems, chemicals, reagents, and services in Israel to hospitals, health management systems, and academic research institutes. Durviz distributes NGS reagents and library preparation systems in Spain and Portugal. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.